PETACH-TIKVA, Israel--Compugen here has begun shipping BioXL, its newest high-end sequence analysis computer system designed for target discovery. The scalable system includes proprietary components on both the hardware and the software side. "With BioXL's superior functionality, algorithmic range, and computational power that scales to more than 50-gig matrix cell updates per second, our clients can now enjoy the ultimate solution for sequence data mining," claimed Meir Yedidia, Compugen's marketing manager of sequence analysis products.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.